Acquired Immunodeficiency Syndrome (AIDS) is the most severe stage of HIV infection, when a person’s CD4 cell count drops below 200 cells/mm and the person’s immune system is no longer able to control viral infection. AIDS is caused by Human Immunodeficiency Virus (HIV). It is transmitted sexually, via blood transfusions, sharing intravenous needles, and from the mother to a child during the birth process and breastfeeding.
DelveInsight’s “Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Acquired Immunodeficiency Syndrome (AIDS), historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome (AIDS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some facts of the AIDS Market Report are:
- According to the latest estimates from the CDC, approximately 34,800 new HIV infections were diagnosed in the United States in 2019.
- CDC estimates of annual HIV infections in the United States show a declining trend in recent years.
- At year-end 2019, an estimated 1.2 million people in the United States aged 13 and older had HIV.
- According to another CDC report, of the estimated 1.2 million people with HIV (diagnosed and undiagnosed) in 2019, about 65.9% received some HIV care, 50.1% were retained in care, and 56.8% were virally suppressed or undetectable.
- Transgender people accounted for approximately 2% of new HIV diagnoses in 2019. There is an increasing need for updated HIV drugs that can treat prevalent patient population as it faces challenges like Multi-Drug Resistance, declining-response to ART (Anti-retroviral therapy). This poses a great opportunity to exploit, considering significant disease burden in 7MM. AIDS Market looks robust with a long pipeline of both drugs & vaccines candidates.
View Report: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market
Request for Sample Report: https://www.delveinsight.com/sample-request/acquired-immunodeficiency-syndrome-aids-market
Treatment of AIDS is focused on the opportunistic illness or condition and decreasing the HIV viral load and monitoring for an increase in CD4 cells through antiretroviral therapy (ART.) VOCABRIA (Cabotegravir) is a human immunodeficiency virus type-1 (HIV-1) integrase strand transfer inhibitor. The multi-class combination drugs segment holds the largest market share as it involves the most advanced technique used for the treatment of HIV infection.
Furthermore, this is attributed to the increase in adoption, owing to their better results in the control of HIV & related co-infections and their ease in consumption & adherence.
The prevalence of HIV/AIDS has increased over recent years with advancements in treatment allowing patients to live longer with HIV. However, there has been a reduction in incidence numbers since the 1990s. While efforts in developed countries have led to improvements in mortality, quality of life, and transmission rates. Nonetheless, US leads the market with major share, by geography among the 7MM.
View Report: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market
Request for Sample Report: https://www.delveinsight.com/sample-request/acquired-immunodeficiency-syndrome-aids-market
Some of Acquired Immunodeficiency Syndrome Companies are:
- ViiV Healthcare
- Johnson and Johnson
- Aelix Therapeutics
- Gilead
- And Many Others
Acquired Immunodeficiency Syndrome Therapies covered:
- Cabotegravir (Vocabria)
- VAC89220
- HTI Immunogen Sequence
- bNAbs (GS-5423 + GS-2872)
- And Many Others
View Report: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market
Request for Sample Report: https://www.delveinsight.com/sample-request/acquired-immunodeficiency-syndrome-aids-market
Table of Contents:
- Key Insights
- Executive Summary of Acquired Immunodeficiency Syndrome (AIDS)
- Competitive Intelligence Analysis for Acquired Immunodeficiency Syndrome (AIDS)
- Acquired Immunodeficiency Syndrome (AIDS): Market Overview at a Glance
- Acquired Immunodeficiency Syndrome (AIDS): Disease Background and Overview
- Patient Journey
- Acquired Immunodeficiency Syndrome (AIDS) Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Acquired Immunodeficiency Syndrome (AIDS) Treatment
- Marketed Products
List to be continued in report
- Emerging Therapies
List to be continued in report
- Acquired Immunodeficiency Syndrome (AIDS): Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview of Acquired Immunodeficiency Syndrome (AIDS)
- KOL Views
- Market Drivers
- Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
Get in touch with our Business executive for Regulatory Analysis, Licensing Services, and Consulting Solutions
Other Links:
- Acquired Immunodeficiency Syndrome (AIDS) Market
- Bladder pain syndrome Market
- Cardiac Arrythmia Market
- Cardiorenal Syndrome Market
- Carpal Tunnel Syndrome Market
- Central Retinal Venous Occulsion Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
Connect With Us at: